GlassScriptPhysician profile
Gary L Miller
NPI 1942390208
$12,148.53
in general payments reported to CMS, 2019-2025
37 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,613 · 2020: $595 · 2021: $385 · 2022: $1,299 · 2023: $1,970 · 2024: $2,322 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,267.86 | 2019-2025 | |
| Boston Scientific Corporation | $1,477.97 | 2019-2025 | Watchman Flx, Watchdog |
| E.R. Squibb & Sons, L.L.C. | $1,357.53 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $931.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.06 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $646.66 | 2019-2024 | Xarelto |
| Amgen INC. | $561.96 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $467.15 | 2020-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $379.62 | 2019-2025 | Farxiga, Brilinta |
| Novo Nordisk INC | $373.88 | 2022-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $331.57 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $278.44 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $258.40 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $219.94 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.82 | 2019-2024 | Lifevest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $174.27 | 2022-2025 | Nexletol |
| Abbott Laboratories | $163.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $158.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.10 | 2022-2025 | |
| Medtronic, INC. | $148.80 | 2022-2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Sanofi-Aventis U.S. LLC | $138.54 | 2019 | |
| Daiichi Sankyo INC. | $131.73 | 2023-2024 | Injectafer |
| Cvrx, INC. | $104.46 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $86.25 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $72.83 | 2023-2024 | Inpefa |
| Bardy Diagnostics, INC. | $55.00 | 2019 | |
| Abiomed | $50.47 | 2023-2024 | Impella |
| Gilead Sciences, INC. | $43.82 | 2019 | |
| Lantheus Medical Imaging, INC. | $41.77 | 2019-2023 | Definity |
| Edwards Lifesciences Corporation | $32.60 | 2025 | |
| Baxter Healthcare | $31.56 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Genzyme Corporation | $29.20 | 2019 | |
| Medtronic Vascular, INC. | $26.80 | 2019 | |
| Philips North America LLC | $24.20 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $24.14 | 2021-2025 | Rhythm Express |
| Bridgebio Pharma, INC. | $22.39 | 2025 | Attruby |
| Mannkind Corporation | $19.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.